Group items tagged

Two new medications which fight drug-resistant superbugs could soon become available to NHS patients in England after the National Institute for Health and Care Excellence (NICE) said they offered value for money. NICE said Cefiderocol and ceftazidime-avibactam will be the first antimicrobial drugs to be made available as part of a subscription-style payment model that incentivises research and development of antimicrobials by testing new approaches to evaluating and paying for them. As part of part of a project with the NHS and the Department of Health and Social Care, the new payment model is designed to address the growing threat posed by antimicrobial resistance - a serious global problem - which develops when the pathogens that cause infection evolve to make antibiotics and other antimicrobial drugs less effective or stop them from working altogether.

Researchers at at an Australian university have developed a new form of antibiotic that can be swiftly re-engineered to avoid resistance to dangerous superbugs. The antibiotic, which was developed by PhD candidate Priscila Cardoso and major supervisor Dr Celine Valery from RMIT's School of Health and Biosciences, has a basic architecture that allows it to be generated quickly and cheaply in a lab. The antibiotic, Priscilicidin, has tiny amino acid building blocks that allow it to be tailored to combat various types of antimicrobial resistance. With the World Health Organization calling antimicrobial resistance "one of the top ten global public health threats facing humanity", developing new antibiotics has become more urgent than ever. Professor Charlotte Conn, one of Cardoso's PhD supervisors, said given that urgency, Priscilicidin was an exciting breakthrough for public health. Priscilicidin is a type of antimicrobial peptide. These peptides are produced by all living organisms as the first defence against bacteria and viruses.

The government has launched the Global AMR Innovation Fund (GAMRIF) on Monday (22 May), under which it has announce up to £39 million fund for antimicrobial resistance (AMR) research. Of this new funding package, up to £24 million over four years has been awarded to bolster the UK's partnership with CARB-X - a global AMR research initiative - to support the continued early development of invaluable new antibiotics, vaccines, rapid diagnostics and other products to combat life threatening drug-resistant infections and prevent death and disease across the world. In addition to the CARB-X grant, GAMRIF is investing £5 million over two years into the Global Antibiotic R&D Partnership (GARDP) to develop - and ensure global access to - new antibiotic treatments against major global health priorities. The announcement comes as Health Minister Will Quince attends the World Health Assembly (WHA) in Geneva, Switzerland, and Development Minister Andrew Mitchell participates in an event on health leadership and climate change alongside the WHA. They will announce the launch of the UK government's Global Health Framework for 2023-2025, as part of Minister Quince's address at the WHA. Health Minister Will Quince said: Antimicrobial resistance is a major threat to global health and has led to millions of tragic deaths per year, but the Global AMR Innovation Fund is supporting cutting-edge research and developing vital new treatments to prevent death and disease across the world.

The NHS has signed the first-of-its-kind subscription deal for two antimicrobial drugs - cefiderocol and ceftazidime-avibactam, manufactured by Shionogi and Pfizer respectively - that will help around 1700 patients per year with severe bacterial infections. Under this deal, pharmaceutical firms will receive a fixed yearly fee - capped at a level that represents value to taxpayers - in order to incentivise funding for innovation that can generate a pipeline of new antibiotics for NHS patients. NHS said the deal will help patients with serious infections that have evolved so much that antibiotics and other current treatments are no longer effective can be given a potentially life-saving alternative. The drugs will provide a lifeline to patients with life-threatening infections like sepsis, hospital or ventilator pneumonia and blood stream infection. Announcing the deal at NHS ConfedExpo, NHS Chief Executive Amanda Pritchard called the revolutionary subscription deal a game-changer and the latest NHS success in using its commercial power to benefit NHS patients in line with the NHS Long Term Plan. "Superbug-busting drugs on the NHS will save lives and strike a blow in the global battle against antimicrobial resistance," Pritchard said.

The Association of the British Pharmaceutical Industry (ABPI) has welcomed the National Institute for Health and Care Excellence's leadership in introducing a new approach to the evaluation of antibiotics. On Tuesday (12 April), NICE published a draft guidance to tackle antimicrobial resistance under which two new antimicrobial drugs - cefiderocol and ceftazidime-avibactam - became the first to be made available as part of the UK's innovative subscription-style payment model. Commenting on the announcement of the new draft guidance, Richard Torbett, chief executive of the ABPI, said: "This is an important milestone in the UK's global leadership on AMR. Antibiotics underpin modern medicine, but the increasing threat of antibiotic resistance remains one of the biggest global health challenges we face. "To tackle this, it is critical that the appropriate frameworks are in place for companies to invest the billions of pounds required to discover the new antibiotics needed for patients.

Cipro is a synthetic broad spectrum antimicrobial agent for oral administration. As a fluoroquinolone derivative, its work is to target the DNA gyrase of the bacterial cell during DNA synthesis. This is the precursor stage for replication & growth of the bacteria, but with Cipro's effect of binding to the DNA and inhibiting cell growth, the bacteria breaks down and is killed.

Karma Vip 515 The VIP 515 is a revolutionary lightweight folding tilt in space wheelchair that uses exclusive perfectly-matched gas struts for an intelligent center-of-gravity weight shifting seat which provides wheelchair users a wide choice of tilt- in-space angles. The VIP reaches unprecedented pressure releasing effects to reduce the risk of bedsores.The end result is the relaxed and peaceful mind and body of users.A folding, attendant propelled, tilt in space wheelchair with a removable adjustable height headrest and a folding backrest. If features an ergonomically designed curved seat, height adjustable, lift up armrests and swing away legrests. Features: Intelligent 0-35 center-of-gravity weight shifting Tilt-in-space seat shifts pressure to reduce pressure sores. aegis Microbe Shield permanently bonded antimicrobial barrier upholstery protects from odor, staining and deterioration from bacteria, fungus and other microorganisms. Bio-technology: paint coating uses special anti-Bacterial materials. Collapses to only 77x34x77cm when the backjoint is folded and headrest removed for easy transport. Height adjustable flip-back armrests. Karma Premium Wheelchair Aurora 4 F24 Wheel chairs are among the most important products in the health and mobility aids segment, as these are one of the main tools used in transferring the immobile, and are needed at all times, both in homes as well as in hospitals. Wheel chairs are needed in public places as well, such as airports and railway stations, where the elderly or the invalid need to be moved into a vehicle. At such times, it helps to be aided by a wheel chair that combines the best of technology and facilities, without being too heavy or cumbersome. And the Karma Premium Wheel Chair Aurora 4 F24 is the ideal product to pick. Armed with detachable headrests and armrests and an elevating footrest, this chair provides the user maximum comfort. With its light-weight metal frame, this wheel chair is easy to

Reclining wheelchairs are available in standard folding frames with extended head supports and seat widths up to 24" wide. The recline mechanism is attendant operated with levers much like a bicycle brake lever. The levers operate hydraulic (pump) mechanisms for a smooth adjustment. Reclining wheelchair divided into two categories- karma km 5000 wheelchair vip 515 reclining wheelchair karma km-5000 wheelchair Karma KM-5000 wheelchair is one of the lightest reclining wheelchair. Karma KM-5000 is highly versatile with a full reclining action from the vertical to the horizontal, combined with fully elevating and swing away leg rests, quick release wheels and removable arm rests. Karma Recline Wheelchair KM-5000 Recline Wheelchair is a highly versatile foldable aluminum transit wheelchair especially designed with a reclining backrest that allows the carrier to continuously adjust from a 90 degree sitting position to a more relaxed 163 degree resting position or any angle in between. Entirely detachable arm-rests enable the user to transfer safely & easily. Also, the elevating and swing-away footrests allow users to adjust to the most comfortable position according to their individual requirements. Karma Ultra Lightweight Km-5000 Recliner Wheelchair is a high strength, lightweight wheelchair is in a league all its own. The reclining range is 90° to 163° and the compact folding design make it ideal for storage or transportation. Additionally, the lightweight, aircraft-grade aluminum frame makes the chair weigh only 36 lbs. Features: Ultra-lightweight aircraft-grade aluminum alloy frame. Bio-technology: paint coating uses special anti-Bacterial materials. Detachable armrests and elevating footrests. Foldable frame with anti-tippers. Detachable and height-adjustable headrest. Backrest reclines smoothly from 90-163. Detachable and height-adjustable headrest. vip 515 reclining wheelchair VIP-515 Reclining Wheelchair is a lightweigh

Ergonomics is the relationship of the body to work. It has long been a priority in industrial settings like assembly plants where work injury from physical overuse is a great danger. Now that computers are causing a lot of physical discomfort, the term is more widely heard.Ergonomic Wheelchairs (Intelligent s-shaped ergonomic seating) provides efficient pressure relief by spreading weight over a greater area, at the same time provides stabilization and reduced sliding. Removable upholstery is equipped with AEGIS Microbe Shield anti-biotic technology, odor and stain resistan, ergonomic & lightweight with compact, wider arm pad that provide comfort support. It has a folding backrest. Ergonomic Wheelchair features an ergonomic "S" shaped seat that provides the perfect shape to fit the human body to relieve pressure, increase stabilization, weight distribution and lower the risk of pressure sores and scoliosis. Features- Ultra-Lightweight Frame & Riggings Ergonomic S-Shape Seat Frame Ergonomic grip built into the wheels you propel yourself in Relieves pressure throughout your body T6 Aircraft Grade Aluminum Fusion of form and function at its best with modern stylish designs and options Tube In Center designed footrests protects legs from impacts Extra wide and ergonomic concave arm pads and foldable backrest Flip back armrests allows for easier transfers Removable footrests S-Ergo 105 Wheelchair S-Ergo 105 is equipped with the unique ergonomic S-shaped seating system.Ergonomic S-shaped seating system, which has been developed by Karma's very own research and development wheelchair team, is proven to be the best in pressure relief and prevent sliding.S-Ergo 105 Wheelchair provides pressure relief, stabilization and reduced slidingExtended armrest design allows better seating space with a narrower total chair widthWider armpad offers comfortable support and the new arm tube design allows easier movement"Tube-in-center" new footplate design assu

Strengthens Immunity Being rich in potent antioxidants & antimicrobial properties, tulsi works as a natural herbal immune functions enhancer, keeping you protected & safe from frequent illnesses, while boosting your immune power to the ultimate level. Better Purification Fighting with the impurities you are getting from unhealthy foods, pollution & human activities, tulsi helps in cleansing and purification by protecting against natural toxins produced within the body. Improves Respiratory Health Tulsi has amazing anti-inflammatory effects that helps reduce inflammation in sore throat and helps get relieve from seasonal cough and cold in an easy and convenient way. Enhances Vitality Tulsi works as a great stress manager that helps maintain normal bodily functions, responsible for happiness & energy. While boosting your metabolism it helps reduce stress & anxiety, making it an ideal concoction for your true well-being.

Looking for something that can help you in being overall better & healthy? Why wandering for such artificial foods & potions! when nature has given you the amazing herbs from the beauty of Ayurveda. Let us take you to the goodness of Giloy and Mulethi that's been used since time immemorial in herbal preparations for their extensive health benefits in human beings. Better Health Starts With The Power Of Ayurvedic Herbs! Boosts Immunity Giloy- The powerhouse of antioxidants to help fight seasonal infections and help you stay protected against regular illnesses with a stronger immunity. Better Liver Health Studies show giloy has hepatoprotective activities, means it helps in removing toxins, purifying body and restoring liver health. Enhances Digestion As per studies, Mulethi helps relieve stomach discomforts like- indigestion, upset stomach, heartburn & may help maintain gut health. Improves Respiratory Health Mulethi- An age old herb for sore throat due to its anti-inflammatory & antimicrobial activities, that helps clear throat airways & fights frequent seasonal cough & cold.

The NHS has launched plans to expand pioneering subscription-style drug contracts to develop lifesaving antibiotics of the future. It is building on its world-first pilot to incentivise the pharmaceutical industry to develop new antibiotics that could be offered to NHS patients when they need them the most. The consultation has launched almost a year to the day that contracts for two superbug-busting drugs were rolled out as part of a world-first pilot. Cefiderocol and ceftazidime-avibactam, new antibiotics manufactured by Shionogi and Pfizer respectively, were awarded world-first subscription contracts which provided the companies with a fixed annual fee based primarily on the availability of the drugs and their value to the NHS, as opposed to the volumes used. By breaking the link between the payments companies receive and the number of their antibiotics prescribed, the NHS is removing any incentive to overuse antibiotics, decreasing the risk of life-threatening infections, such as sepsis and pneumonia, becoming resistant to treatment.

Pharmacy professionals to be included as key stakeholders in the implementation, delivery and evaluation of a wide range of genomic services, said the Royal Pharmaceutical Society (RPS). RPS's statement has been developed in collaboration with pharmacy organisations who have co-badged the report, such as the British Oncology Pharmacy Association, the UK Clinical Pharmacy Association, Association of Pharmacy Technicians and the College of Mental Health Pharmacy. It looks at current and future roles for pharmacy professionals in genomic medicine across many aspects of practice such as person-centred care and collaboration, professional practice, education, leadership, management and research. Pharmacists and pharmacy technicians in the UK have already established roles in the application of genomic medicine in some areas of practice, such as antimicrobial stewardship and infectious diseases, and the management of certain genetic conditions, such as cystic fibrosis. The society believes, the current role of pharmacy professionals in genomics can be expanded upon in the future to both lead and support many relevant aspects of genomic implementation. These are described across all healthcare sectors, within the Genome UK strategy produced by the UK Government, and within the implementation plans published in England, Scotland and Wales. Lead for Pharmacogenomics at RPS Sophie Harding said: "Pharmacy professionals are the gatekeepers of medication safety and efficacy across all areas of healthcare. They are skilled at interpreting complex scientific data and use evidence-based medicine to maximise the benefits of treatments for patients, whilst supporting shared decision-making with patients and the multidisciplinary team.

You've heard the beauty benefits of turmeric from your grannies; you may know how turmeric soap benefits your skin. Many studies advocate curcumin's skin-lightening effects, a polyphenol emanating from turmeric. There's also evidence to back its anti-inflammatory and antimicrobial features. Meanwhile, it's a rich source of antioxidants. The golden powder is not only for flavoring up curries; it is also a mainstay in Ayurvedic therapies, both as a tonic and as a beauty agent. The purported skin benefits of this natural turmeric soap include: Skin Whitening Benefits Skin Conditions Fades dark spots Treats acne Fight Aging Meeting any beauty assertions with a healthy dose of suspicion is wise. (After all, if you've ever undergone distressing skincare bents such as peel-off masks, you might think twice before going for other trends.) Fortunately, turmeric soap emerges to deliver benefits to the skin. Turmeric Soap Benefits Although not tangible, analyses indicate that turmeric will soon become a low-cost substitute for relieving skin diseases like eczema, alopecia, etc. Soaping with a turmeric soap bar can help you enhance your skin health in numerous ways. And what's more? Here are excellent turmeric soap benefits that will improve your overall skin health. Turmeric Soap Benefits Blood Circulation that results in Skin Whitening. If your major skin issue is dullness, try to check out turmeric since it's a natural exfoliator. Numerous animal and test-tube studies have shown that turmeric and curcumin extract can boost glutathione levels. Researchers conclude that the curcumin found in turmeric can assist in restoring adequate levels of glutathione and improve the activity of glutathione enzymes. It has the power to slough off your dead skin cells, remove pollutants, and clear oil or makeup build-up, leaving you with a smooth and healthy glow. Regular use of turmeric soap benefits your skin's glow and brightens it naturally. This is why turmeric is also

Community Pharmacy England (CPE) is aiming to reach an agreement with the Department of Health and Social Care (DHSC) and NHS England (NHSE) on negotiation with regards to expanded services and payment model in the pharmacy sector. Chief Executive Janet Morrison, said: "We are working at pace in negotiations with DHSC and NHSE. The process remains on track with the Government's original timescale - i.e. aiming for agreement in July, with cross-government clearance later in July, and implementation from July through to September." CPE is involved in working groups on service expansion of Hypertension Case-Finding and the Pharmacy Contraception Scheme and service design for the Common Conditions Service; and are in in-depth negotiations on Payment models. These discussions critically look at the balance between funding core capacity and activity payments, how the funding streams will be distributed and how CPE will measure delivery and impact. NHSE has been leading on the development of the PGD pathways for each of the 7 conditions, with external medical, pharmacy and other experts feeding into the process - pharmacy owners from the Community Pharmacy England Committee have also been involved but the discussions are clinically led to ensure they comply with NICE principles and concur with Antimicrobial Stewardship policy.

The UK Health Security Agency (UKHSA) has published the latest national surveillance data on antibiotic prescribing and resistance. The English surveillance programme for antimicrobial utilisation and resistance (ESPAUR) report showed an increase in antibiotic use in all settings (apart from dental) in 2022. According to the report, antibiotic prescribing rose by 8.4 per cent in 2022 compared with 2021, although the number remains below 2019 pre-pandemic levels. "There are many reasons behind the increase in prescribing, one of which is likely related to decreased immunity and exposure to infections during the COVID-19 pandemic that may have underpinned the increased transmission in co-circulating infections, namely: influenza (flu), respiratory syncytial virus (RSV) and group A streptococcus (GAS)," the report stated.

The current structure of global incentives to develop new antibiotics is insufficient and requires urgent resolution revealed a new report 'Incentivising new antibiotics' by the Office of Health Economics (OHE). OHE analysis demonstrates that on a global level, it is estimated that an effective 10-year incentive would require £3.5bn ($4.2bn) to adequately cover the entire research and development process for a new antibiotic. The report considers how health systems in the UK and around the world can stimulate the research and development (R&D) of new antibiotics. In 2020, the National Institute for Health and Care Excellence (NICE) and NHS England initiated an Antimicrobial Resistance pilot with the aim of incentivising pharmaceutical companies to develop new antibiotics by addressing the issues associated with reimbursement, which historically has deterred companies from pursuing AMR research.

Researchers from the London School of Hygiene & Tropical Medicine (LSHTM) have been tasked to evaluate the impact, safety and effectiveness of the Pharmacy First service, which was launched across England in January 2024. They have been awarded £2.4million by the National Institute for Health and Care Research (NIHR) to generate evidence on the new service that allows pharmacies to provide advice and treatment for seven common conditions without the need for a GP appointment. After consultation, if necessary, a community pharmacist can supply some prescription-only medicines to treat earache, sore throat, sinusitis, impetigo, shingles, infected insect bites or uncomplicated urinary tract infections in women. The LSHTM researcher team will be working together with experts at the UK Health Security Agency (UKHSA) and the Universities of Oxford, Manchester and Nottingham on the project. Dr Rebecca Glover, assistant professor in Antimicrobial Resistance at LSHTM, who will lead the three-year project, said they will evaluate "Pharmacy First's impact on GPs and the wider NHS, pharmacy services and patients."

The VIP 515 is a revolutionary lightweight folding tilt in space wheelchair that uses exclusive perfectly-matched gas struts for an intelligent center-of-gravity weight shifting seat which provides wheelchair users a wide choice of tilt- in-space angles. The VIP reaches unprecedented pressure releasing effects to reduce the risk of bedsores.The end result is the relaxed and peaceful mind and body of users.A folding, attendant propelled, tilt in space wheelchair with a removable adjustable height headrest and a folding backrest. If features an ergonomically designed curved seat, height adjustable, lift up armrests and swing away legrests. Features: Intelligent 0-35 center-of-gravity weight shifting Tilt-in-space seat shifts pressure to reduce pressure sores. aegis Microbe Shield permanently bonded antimicrobial barrier upholstery protects from odor, staining and deterioration from bacteria, fungus and other microorganisms. Bio-technology: paint coating uses special anti-Bacterial materials. Collapses to only 77x34x77cm when the backjoint is folded and headrest removed for easy transport. Height adjustable flip-back armrests.